Mitragynine-Induced Conditioned Place Preference (CPP) And The Profiles Of Dopamine And Its Metabolites In Rats by Yusoff, Nurul Hasnida Mohammad
  
 
 
MITRAGYNINE-INDUCED CONDITIONED 
PLACE PREFERENCE (CPP) AND THE 
PROFILES OF DOPAMINE AND ITS 
METABOLITES IN RATS 
 
 
 
 
 
NURUL HASNIDA BINTI MOHAMMAD YUSOFF 
 
 
 
 
 
 
UNIVERSITI SAINS MALAYSIA 
2018 
 
  
 
 
MITRAGYNINE-INDUCED CONDITIONED 
PLACE PREFERENCE (CPP) AND THE 
PROFILES OF DOPAMINE AND ITS 
METABOLITES IN RATS 
 
 
 
by 
 
 
 
NURUL HASNIDA BINTI MOHAMMAD YUSOFF 
 
 
 
Thesis submitted in fulfillment of the requirements 
for the degree of 
Doctor of Philosophy  
 
 
 
May 2018 
ii 
 
ACKNOWLEDGEMENT 
 
Assalamualaikum w.b.t. 
First and foremost I thank Allah for endowing me with good health, patience, 
strength and knowledge to complete this work succesfully. 
 
My deepest appreciation and indebtedness goes to my main supervisor, Assoc. Prof. 
Dr. Zurina Hassan for the exemplary guidance and constant encouragement 
throughout this project. Not forgotten, my field supervisor, Prof. Christian Muller, 
who has provided me with new experimental skills and knowledge which I have 
gained throughout my practical training in Friedrich-Alexander-University, 
Erlangen-Nuremberg, Germany. His expert guidance and valuable suggestions are 
very much appreciated.  Also, I would like to express my gratitude to Dr. Davide 
Amato and Dr. Fabio who had trained me on the brain microdialysis and animal 
behavioural techniques. To my co-supervisor, Prof. Emeritus Visweswaran 
Navaratnam and Dr. Lai Choon Sheen, thank you for your help and kindness. 
 
Special thank goes to Prof. Sharif Mahsufi Mansor, the former Director of the Centre 
for Drug Research (CDR), Universiti Sains Malaysia, for his guidance and the 
facilities provided. A thousand thank to all the CDR staffs, especially Mr. Asokan 
A/L Muniandy, for helping me during the course of this study. The completion of 
this project could not have been possible without the assistance of so many people 
whose names may not all be mentioned here. Their contributions are sincerely 
appreciated and gratefully acknowledged.  
iii 
 
To my beloved husband, Tengku Ikmal Bahrin bin Tengku Endut, thank you for the 
endless support, kind and understanding, and for taking care of our kids, Tengku 
Farhah Atiqah and Tengku Muhammad Faris, while completing the work. I further 
extend my heartfelt gratitude to my parents, Mohammad Yusoff Hassan and 
Zubaidah Md. Zin, and my siblings, Nurul Fahada, Mohammad Azizzir Hizmi, 
Mohammad Hidzir, Nurul Fahadis and Nurul Sufieha, whose words of advice, care, 
unconditional love, strength and support have brought me here. 
 
I am so lucky and fortunate to have very supportive friends, Farah Wahida Suhaimi 
and Nur Najihah Ismail, who are always being with me during my ups and downs. 
Also to my lab mates, Norsyifa Harun, Nor Fasihah Azam, Thenmoly and Nurul 
Aqmar Mohamad Nor Hazalin, thank you for making my life more cheerful and 
meaningful. 
 
Last but not least, this research project was supported by the Higher Education 
Centre of Excellence (HiCoE) special funding (304/CDADAH/4401009), the 
Fundamental Research Grant Scheme (203/CDADAH/6711469) and MyBrain15 
Scholarship. 
 
Thank you, may Allah bless all of us. 
 
 
Nurul Hasnida Mohammad Yusoff 
iv 
 
TABLE OF CONTENTS 
 
Acknowledgement        ii 
Table of contents        iv 
List of tables xii 
List of figures xiv 
List of abbreviations xviii 
List of symbols xxi 
Abstrak  xxii 
Abstract xxv 
  
CHAPTER 1 – OVERVIEW 1 
1.1 General introduction 1 
1.2 Problem statements 3 
1.3 Objectives 7 
1.4 Summary of the research design 8 
  
CHAPTER 2 – LITERATURE REVIEW 9 
2.1 Drug addiction 9 
2.1.1 Theories of addiction 9 
2.1.2 Neurobiology of addiction 11 
v 
 
2.1.3 Molecular and cellular adaptations in addiction 17 
2.1.4 Drugs of abuse 18 
2.1.5 Drug dependence and relapse (reinstatement) 20 
2.1.6 Animal models of addiction 22 
2.1.6(a) Intracranial electrical self-stimulation 23 
2.1.6(b) Drug self-administration 23 
2.1.6(c) Conditioned place preference (CPP) 24 
2.1.7 Neurochemical analysis of dopamine via microdialysis 27 
2.2 Mitragyna speciosa Korth 30 
2.2.1 Plant description 30 
2.2.2 Plant use and preparations 31 
2.2.3 Legality 33 
2.2.4 Phytochemistry 34 
2.2.5 Pharmacokinetic 36 
2.2.6 Metabolism and detection 38 
2.2.7 Side effects and toxicology 39 
2.2.8 Pharmacological and physiological effects 41 
2.2.9 Abuse liability 48 
  
 
 
 
vi 
 
CHAPTER 3 – GENERAL METHODOLOGY 52 
3.1 Subjects 52 
3.2 Mitragynine preparation 52 
3.3 CPP 53 
3.3.1 CPP apparatus 53 
3.3.2 CPP procedure 54 
3.3.3 Experimental design for the involvement of receptor systems on 
acquisition and expression of mitragynine-induced CPP 
56 
3.3.3(a) Effect of receptor agonist/antagonist on acquisition of 
mitragynine-induced CPP 
56 
3.3.3(b) Effect of receptor agonist/antagonist on expression of 
mitragynine-induced CPP 
57 
3.4 Statistical analysis 57 
  
CHAPTER 4 – EFFECTS OF MITRAGYNINE ON LOCOMOTION 
AND ADDICTIVE BEHAVIOURS (REWARDING PROPERTIES 
AND RELAPSE) 
58 
4.1 Introduction 58 
4.2 Methodology 61 
4.2.1 Subjects 61 
4.2.2 Drugs preparation 61 
4.2.3 Experimental protocols 61 
vii 
 
4.2.3(a) Establishment of mitragynine-induced CPP and the 
locomotor effects 
63 
4.2.3(b) Maintenance of mitragynine-induced CPP 63 
4.2.3(c) Extinction and reinstatement of mitragynine-induced 
CPP 
64 
4.3 Results 66 
4.3.1 Establishment of mitragynine-induced CPP and the locomotor 
effects 
66 
4.3.2 Maintenance of mitragynine-induced CPP 71 
4.3.3 Extinction and reinstatement of mitragynine-induced CPP 73 
4.4 Discussion 75 
  
CHAPTER 5 - INVOLVEMENT OF OPIOID RECEPTOR SYSTEM 
ON MITRAGYNINE-INDUCED CONDITIONED PLACE 
PREFERENCE 
85 
5.1 Introduction 85 
5.2 Methodology 85 
5.2.1 Subjects 87 
5.2.2 Drugs preparation 87 
5.2.3 Experimental protocols 87 
5.2.3(a) Effect of naloxone on acquisition of mitragynine-induced 
CPP 
 
87 
viii 
 
5.2.3(b) Effect of naloxone on expression of mitragynine-induced 
CPP 
89 
5.3 Results 90 
5.3.1 Effect of naloxone on acquisition of mitragynine-induced CPP 90 
5.3.2 Effect of naloxone on expression of mitragynine-induced CPP 95 
 5.4 Discussion 98 
  
CHAPTER 6 - INVOLVEMENT OF GABAB RECEPTOR SYSTEM 
ON MITRAGYNINE-INDUCED CONDITIONED PLACE 
PREFERENCE 
104 
6.1 Introduction 104 
6.2 Methodology 107 
6.2.1 Subjects 107 
6.2.2 Drugs preparation 107 
6.2.3 Experimental protocols 107 
6.2.3(a) Effect of baclofen on acquisition of mitragynine-
induced CPP 
107 
6.2.3(b) Effect of baclofen on expression of mitragynine-
induced CPP 
109 
6.2.4 Statistical analysis 110 
6.3 Results 111 
6.3.1 Effect of baclofen on acquisition of mitragynine-induced CPP 111 
ix 
 
6.3.2 Effect of baclofen on expression of mitragynine-induced CPP 117 
6.4 Discussion 121 
  
CHAPTER 7 - EFFECTS OF ACUTE MITRAGYNINE EXPOSURE 
ON EXTRACELLULAR BRAIN DOPAMINERGIC PROFILE 
127 
7.1 Introduction 127 
7.2 Methodology 129 
7.2.1 Subjects 129 
7.2.2 Drugs preparation 129 
7.2.3 Surgery 129 
7.2.4 Isoflurane anaesthesia 131 
7.2.5 Microdialysis procedure 131 
7.2.6 Experimental design 133 
7.2.7 HPLC method validation and chromatographic analysis 133 
7.2.7(a) Preparation of stock solutions, calibration standards and            
quality control samples 
135 
7.2.7(b) Selectivity 136 
7.2.7(c) Linearity of calibration curves, range and determination 
of lower limit of quantification 
136 
7.2.7(d) Accuracy, precision and recovery 137 
7.2.7(e) Stability 138 
7.2.7(e)(i) Freeze and thaw stability 138 
x 
 
7.2.7(e)(ii) Short-term stability 138 
7.2.7(e)(iii) Long-term stability 138 
7.2.7(e)(iv) Stock solution stability 139 
7.2.7(e)(v) Autosampler stability 139 
7.2.8 Statistical analysis 139 
7.3 Results 140 
7.3.1 Method validation 140 
7.3.1(a) Selectivity 140 
7.3.1(b) Linearity of calibration curves, range and determination 
of LLOQ 
143 
7.3.1(c) Accuracy, precision and recovery 143 
7.3.1(d) Stability 147 
7.3.2 Chromatographic analysis 149 
7.4 Discussion 158 
  
CHAPTER 8 - GENERAL CONCLUSION 163 
8.1 Summary of the research findings 163 
8.2 Limitations of the study 165 
8.3 Recommendations for future research 166 
  
  
xi 
 
References 168 
Appendices  
List of publications  
Local and international conferences  
xii 
 
LIST OF TABLES 
  Page 
Table 2.1 Reported alkaloids isolated from M. speciosa Korth. 35 
Table 4.1 Drugs administered during extinction and drug 
reinstatement procedure. 
65 
Table 5.1 Treatment groups for the study of the effect of naloxone 
on acquisition of mitragynine-induced CPP. 
88 
Table 5.2 Treatment groups for the study of the effect of naloxone 
on expression of mitragynine-induced CPP. 
89 
Table 6.1 Treatment groups for the study of the effect of baclofen on 
acquisition of mitragynine-induced CPP. 
108 
Table 6.2 Treatment groups for the study of the effect of baclofen on 
expression of mitragynine-induced CPP. 
109 
Table 7.1 Regression statistics of the calibration functions for 
dopamine, dihydroxyphenylacetic acid and homovanillic 
acid. 
143 
Table 7.2 Accuracy and precision of dopamine, 
dihydroxyphenylacetic acid and homovanillic acid in 
microdialysate calibrators. 
144 
Table 7.3 Intra-day and inter-day accuracy and precision of 
dopamine, dihydroxyphenylacetic acid and homovanillic 
acid in microdialysate quality controls. 
145 
Table 7.4 Recovery of dopamine, dihydroxyphenylacetic acid and 
homovanillic acid in microdialysate quality controls. 
146 
xiii 
 
Table 7.5 Stability results for dopamine, dihydroxyphenylacetic acid 
and homovanillic acid. 
148 
Table 7.6 Basal release of dopamine, dihydroxyphenylacetic acid 
and homovanillic acid in the prefrontal cortex, nucleus 
accumbens and caudate putamen region. 
149 
  
xiv 
 
LIST OF FIGURES 
  Page 
Figure 1.1 Research design and the number of animals used in the 
study. 
8 
Figure 2.1 Brain reward circuit. 12 
Figure 2.2 Schematic representation of dopamine synthesis and 
metabolism. 
14 
Figure 2.3 Structure of dopamine and its metabolites. 14 
Figure 2.4 Schematic representation of dialysis probe. 28 
Figure 2.5 Schematic diagram of an on-line microdialysis system. 30 
Figure 2.6 The plant of M. speciosa Korth. 31 
Figure 2.7 Chemical structure of mitragynine and its major 
analogues. 
36 
Figure 3.1 CPP apparatus design. 54 
Figure 4.1 Experimental design for the establishment, maintenance, 
extinction and reinstatement of drug-induced CPP. 
62 
Figure 4.2 Initial preference for each CPP chamber during pre-
conditioning test. 
66 
Figure 4.3 Locomotor activity of rats with different conditioning 
treatments during the four (A) conditioning sessions with 
drug, and (B) conditioning sessions with vehicle. 
68 
xv 
 
Figure 4.4 Drug-induced CPP. 69 
Figure 4.5 Conditioned locomotor effect observed during drug-free 
CPP testing. 
70 
Figure 4.6 The number of entries into drug-paired chamber with 
different conditioning treatments. 
70 
Figure 4.7 The time spent per entry into drug-paired chamber with 
different conditioning treatments. 
71 
Figure 4.8 Maintenance of mitragynine-induced CPP. 72 
Figure 4.9 Expression of the drug priming reinstatement following 
extinction by vehicle pairings. 
73 
Figure 4.10 Locomotor activity during pre-conditioning, extinction 
and reinstatement test. 
74 
Figure 5.1 The effects of naloxone on the acquisition of 
mitragynine-induced CPP. 
91 
Figure 5.2 The effects of naloxone on locomotor activity during the 
acquisition of mitragynine-induced CPP. 
94 
Figure 5.3 The effects of naloxone on the expression of mitragynine-
induced CPP. 
96 
Figure 5.4 The effects of naloxone on locomotor activity during the 
expression of mitragynine-induced CPP. 
97 
Figure 6.1 The effects of baclofen on the acquisition of CPP. 113 
Figure 6.2 The effects of baclofen on the acquisition of mitragynine-
induced CPP. 
116 
xvi 
 
Figure 6.3 The effects of baclofen on the CPP expression.  118 
Figure 6.4 The effects of baclofen on the expression of mitragynine-
induced CPP. 
120 
Figure 7.1 Representative chromatograms of (A) Ringer solution, 
(B) Ringer solution spiked with dopamine standard at 5 
nM, and blank rat microdialysate sample obtained from 
(C1) prefrontal cortex, (C2) nucleus accumbens and (C3) 
caudate putamen region. 
141 
Figure 7.2 Representative chromatograms of (A) Ringer solution, 
(B) Ringer solution spiked with a mixture of 
dihydroxyphenylacetic acid and homovanillic acid 
standard each at 100 nM, and blank rat microdialysate 
sample obtained from (C1) prefrontal cortex, (C2) 
nucleus accumbens and (C3) caudate putamen region. 
142 
Figure 7.3 Representative chromatograms of microdialysate sample 
obtained from mitragynine-treated rats at 100 min. 
150 
Figure 7.4 The effects of vehicle, methamphetamine, morphine and 
mitragynine administration on extracellular levels of (A) 
dopamine, (B) dihydroxyphenylacetic acid and (C) 
homovanillic acid in prefrontal cortex of conscious freely 
moving rat. 
152 
Figure 7.5 The effects of vehicle, methamphetamine, morphine and 
mitragynine administration on extracellular levels of (A) 
dopamine, (B) dihydroxyphenylacetic acid and (C) 
homovanillic acid in nucleus accumbens of conscious 
freely moving rat. 
154 
Figure 7.6 The effects of vehicle, methamphetamine, morphine and 
mitragynine administration on extracellular levels of (A) 
dopamine, (B) dihydroxyphenylacetic acid and (C) 
homovanillic acid in caudate putamen of conscious freely 
moving rat. 
156 
xvii 
 
Figure 7.7 The effects of vehicle, methamphetamine, morphine and 
mitragynine administration on locomotor activity of 
conscious freely moving rats measured during 
microdialysis. 
157 
 
xviii 
 
LIST OF ABBREVIATIONS 
 
ALT alanine transaminase 
ANOVA analysis of variance 
AP anteroposterior 
AST aspartate aminotransferase 
Cmax maximum serum concentration 
Cmea measured concentration 
Cnom nominal concentration 
Ca
2+
 calcium 
cAMP cyclic adenosine 3’,5’-monophosphate 
Cl
- 
chloride 
Cl/F clearance rate 
CNS central nervous system 
COMT catecholamine-O-methyltransferase 
CPA conditioned place aversion 
CPP conditioned place preference  
CPu caudate putamen 
CRE cAMP response element 
CREB cAMP response element binding protein 
CRF corticotrophin-releasing factor 
CV coefficient of variation 
DA dopamine 
DAT dopamine transporter 
DOPAC 3,4-dihydroxyphenylacetic acid 
DRRF dopamine receptor-regulating factor 
DV dorsoventral 
ECF extracellular fluid 
eg. example 
et al. and others  
fEPSP field excitatory post-synaptic potentials 
FST forced swimming test 
xix 
 
GABA gamma-aminobutyric acid  
GIRK Kir3/G protein-coupled inwardly rectifying K
+
 
7-HMG 7-hydroxymitragynine 
HPA hypothalamic-pituitary-adrenal 
HPLC-ECD high performance liquid chromatography coupled with 
electrochemical detector 
HVA homovanillic acid 
ICSS intracranial electrical self-stimulation 
i.d. internal diameter 
i.p. intraperitoneal 
K
+
 potassium 
L-DOPA L-dihydroxyphenylalanine 
LLOQ lower limit of quantification 
LTP long term potentiation 
M Molar 
MAO monoamine oxidase 
MGM-9 ethylene glycol-bridged and C10-fluorinated derivative of 
mitragynine 
ML mediolateral 
3-MT 3-methoxytyramine 
n number of animals/samples 
NAc nucleus accumbens 
NPY neuropeptide Y 
PFC prefrontal cortex 
QC quality control 
RE relative error 
s.c subcutaneous 
SEM standard error of means 
SN substantia nigra 
t1/2 elimination half life 
Tmax maximum time 
TH tyrosine hydroxylase 
TST tail suspension test 
xx 
 
vs. versus 
VTA ventral tegmental area 
v/v volume over volume 
 
 
 
 
 
 
 
 
 
 
 
xxi 
 
LIST OF SYMBOLS 
  
° degree 
°C degree celcius 
% percent 
- minus 
± plus minus 
X multiply 
= equals to 
/ per (for each) 
µ micro 
µ mu 
< less than 
> more than 
Δ delta 
К kappa 
Ƴ gamma 
ʎz elimination rate constant 
xxii 
 
KECENDERUNGAN TEMPAT BERKONDISI (CPP) TERARUH 
MITRAGININA DAN PROFIL DOPAMINA SERTA METABOLIT-
METABOLITNYA DI DALAM TIKUS 
 
 
ABSTRAK 
 
Mitragyna speciosa (M. speciosa) Korth ialah tumbuhan herba tradisional 
berasal dari Asia Tenggara. Penggunaan tetap tumbuhan ini oleh manusia boleh 
menyebabkan ketagihan dengan simptom-simptom penarikan yang ketara. 
Dihipotesiskan bahawa penyalahgunaan penyediaan-penyediaan M. speciosa 
mungkin disebabkan oleh mitraginina, bahan psikoaktif utama yang dipencilkan dari 
daunnya. Oleh itu, kajian secara komprehensif ke atas sifat-sifat ganjaran 
mitraginina, beserta mekanisma-mekanisma yang terlibat diperlukan. Dalam 
bahagian pertama kajian, sifat-sifat ganjaran mitraginina (1, 5, 10 dan 30 mg/kg) dan 
kesan-kesan lokomotor dikaji di dalam tikus Sprague-Dawley, menggunakan 
paradigma kecenderungan tempat berkondisi (CPP). Sebagai keputusannya, tikus 
yang dikondisi dengan mitraginina menghasilkan CPP pada dos 10 dan 30 mg/kg 
(P<0.05) seperti yang ditunjukkan oleh kecenderungan tikus terhadap persekitaran 
berkondisi mitraginina, tanpa perubahan aktiviti lokomotor pada semua dos yang 
diuji (P>0.05). Tambahan lagi, adalah menarik juga untuk mengkaji sama ada CPP 
teraruh mitraginina kekal semasa ketiadaan mitraginina, dan muncul semula 
berikutan suntikan mitraginina. Dari pemerhatian, CPP teraruh mitraginina (10 
mg/kg) kekal sekurang-kurangnya 7 hari (P<0.001) selepas ujian CPP pertama, 
lenyap selepas 8 latihan pemadaman (P>0.05) dan muncul semula oleh suntikan 
mitraginina (P<0.05). Untuk memahami mekanisma-mekanisma yang menyebabkan 
xxiii 
 
CPP teraruh mitraginina, penglibatan sistem reseptor opioid dan asid gamma-
aminobutirik B (GABAB) dalam fasa pemerolehan dan pengekspresan dikaji. 
Eksperimen-eksperimen dijalankan menggunakan antagonis reseptor opioid, 
nalokson (0.1, 0.3 dan 1.0 mg/kg) dan agonis reseptor GABAB, baclofen (1.25, 2.5 
dan 5.0 mg/kg). Sebagai keputusannya, dalam kajian nalokson, pra-rawatan dengan 
nalokson (0.1-1.0 mg/kg) sebelum kondisi mitraginina menghalang CPP teraruh 
mitraginina (P>0.05) sementara nalokson (0.1-1.0 mg/kg) yang diberi sebelum ujian 
CPP tidak menghalang pengekspresan CPP teraruh mitraginina (P<0.05). Dalam 
kajian baclofen, CPP teraruh mitraginina diperhatikan selepas 1.25 mg/kg baclofen 
tetapi tidak lagi kelihatan selepas 2.5 atau 5 mg/kg baclofen, sama ada diberi 
sebelum kondisi mitraginina atau ujian CPP (P>0.05). Keputusan-keputusan ini 
menunjukkan bahawa CPP teraruh mitraginina dipengaruhi oleh sistem opioid pada 
fasa pemerolehan tetapi tidak pada fasa pengekspresan, sementara sistem reseptor 
GABAB mempengaruhi CPP teraruh mitraginina pada kedua-dua fasa pemerolehan 
dan pengekspresan. Akhir sekali, adalah penting untuk memeriksa sama ada 
mitraginina meningkatkan pengeluaran dopamina (DA) pada kawasan-kawasan 
ganjaran otak seperti yang diperhatikan pada dadah-dadah lain yang disalahgunakan. 
Untuk tujuan ini, pengeluaran DA otak ekstraselular serta metabolit-metabolitnya, 
asid 3,4-dihidroksifenilasetik (DOPAC) dan asid homovanilik (HVA), diperiksa 
dalam korteks prefrontal (PFC), nukleus akumbens (NAc) dan kaudat putamen (CPu) 
berikutan pendedahan mitraginina (10 mg/kg) akut. Daripada penemuan hasil, 
mitraginina tidak mengubah paras DA ekstraselular basal dalam semua bahagian 
otak yang diperiksa (P>0.05), tetapi meningkatkan paras DOPAC dalam CPu (183%; 
P<0.05) dan HVA (P<0.05) dalam PFC (168%), NAc (144%) dan CPu (157%) 
berikutan pemberiannya. Secara keseluruhannya, kajian ini merungkai sifat-sifat 
xxiv 
 
ganjaran mitraginina, dengan terhasilnya CPP teraruh mitraginina. CPP teraruh 
mitraginina boleh dikekalkan dan muncul semula, menunjukkan kehadiran perlakuan 
mendapatkan dadah dan relaps dadah. Penemuan-penemuan ini menyokong peranan 
mitraginina terhadap potensi ketagihan M. speciosa yang dilaporkan dalam manusia. 
Sebagai tambahan, sistem reseptor opioid dan GABAB bertindak sebagai sebahagian 
dari mekanisma-mekanisma melibatkan CPP teraruh mitraginina. Sistem DA 
mungkin memainkan peranan penting dalam mempengaruhi CPP teraruh 
mitraginina, kerana pendedahan mitraginina akut menghasilkan kesan penggalak 
akut terhadap sintesis DA.        
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MITRAGYNINE-INDUCED CONDITIONED PLACE PREFERENCE (CPP) 
AND THE PROFILES OF DOPAMINE AND ITS METABOLITES IN RATS 
 
 
ABSTRACT 
 
Mitragyna speciosa (M. speciosa) Korth is a traditional herbal plant 
indigenous to Southeast Asia. Regular use of this plant by human may lead to 
addiction with profound withdrawal symptoms. It is hypothesized that the abuse of 
M. speciosa preparations could be attributed to mitragynine, the main psychoactive 
compound isolated from its leaves. Therefore, comprehensive studies on the 
rewarding properties of mitragynine, as well as the mechanisms invoved, are needed. 
In the first part of the study, the rewarding properties of mitragynine (1, 5, 10 and 30 
mg/kg) and its locomotor effects were investigated in Sprague-Dawley rats, using a 
conditioned place preference (CPP) paradigm. As a result, rats conditioned with 
mitragynine possesses CPP at dose of 10 and 30 mg/kg (P<0.05) as shown by the 
rats’ preference for mitragynine-conditoned environment, with no changes in 
locomotor activity at all doses tested (P>0.05). Furthermore, it is of interest to 
investigate whether the mitragynine-induced CPP can be maintained in the absence 
of mitragynine, and reinstated following mitragynine administration. From the 
observations, the mitragynine (10 mg/kg)-induced CPP was maintained for at least 7 
days (P<0.001) after the initial CPP test, extinguished after 8 extinction trainings 
(P>0.05) and reinstated by priming mitragynine injection (P<0.05). In order to 
understand the mechanisms underlying the mitragynine-induced CPP, the 
involvement of opioid and gamma-aminobutyric acid B (GABAB) receptor system in 
the acquisition and expression phase was studied. The experiments were performed 
xxvi 
 
using an opioid receptor antagonist, naloxone (0.1, 0.3 and 1.0 mg/kg) and a GABAB 
receptor agonist, baclofen (1.25, 2.5 and 5.0 mg/kg). As a result, in naloxone study, 
pre-treatment with naloxone (0.1-1.0 mg/kg) before mitragynine conditioning 
blocked the mitragynine-induced CPP (P>0.05) while naloxone (0.1-1.0 mg/kg) 
given before the CPP test did not prevent the expression of mitragynine-induced CPP 
(P<0.05). In baclofen study, the mitragynine-induced CPP was observed after 1.25 
mg/kg baclofen but no longer observed after 2.5 or 5 mg/kg baclofen, either given 
before mitragynine conditioning or CPP test (P>0.05). These results showed that the 
mitragynine-induced CPP were mediated by opioid system at the acquisition but not 
expression phase, while GABAB receptor system affects the mitragynine-induced 
CPP at both the acquisition and expression phases. Finally, it is of great importance 
to examine whether mitragynine increases the dopamine (DA) release at brain reward 
areas as seen with other drugs of abuse. For this reason, the release of extracellular 
brain DA and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and 
homovanillic acid (HVA), were monitored in the prefrontal cortex (PFC), nucleus 
accumbens (NAc) and caudate putamen (CPu) following acute mitragynine exposure 
(10 mg/kg). From the findings, mitragynine did not alter the extracellular basal DA 
level in all brain regions examined (P>0.05), but increased DOPAC in the CPu 
(183%; P<0.05) as well as HVA (P<0.05) in the PFC (168%), NAc (144%) and CPu 
(157%) following its administration. Taken together, the present study reveals the 
rewarding properties of mitragynine, by the establishment of mitragynine-induced 
CPP. The mitragynine-induced CPP could be maintained and reinstated, indicating 
the presence of drug-seeking behaviour and drug relapse. These findings support the 
role of mitragynine for the abuse potential of M. speciosa reported in humans. 
Additionally, the opioid and GABAB receptor systems serve as parts of the 
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mechanisms underlying the mitragynine-induced CPP. The DA system may play an 
essential role in mediating the mitragynine-induced CPP, since acute mitragynine 
exposure produced acute stimulating effect on DA synthesis. 
1 
 
CHAPTER 1  
OVERVIEW 
 
1.1 General introduction 
Mitragyna speciosa (M. speciosa) Korth is a plant native to Southeast Asia. It is 
known as ketum in Malaysia and kratom in Thailand (Hassan et al., 2013; Suhaimi et 
al., 2016). It is traditionally used for its medicinal values and stimulatory actions 
(Singh et al., 2018; Suhaimi et al., 2016). Increasing reports on M. speciosa abuse 
and its addictive potential has led to the extensive study of mitragynine, the major 
active alkaloid extracted from M. speciosa leaves (Harun et al., 2015; Sufka et al., 
2014). Mitragynine is believed to be responsible for various pharmacological effects 
exerted by M. speciosa, mainly through opioid receptors (Matsumoto et al., 2005a; 
Taufik Hidayat et al., 2010; Watanabe et al., 1997). Though the M. speciosa extracts 
and its compounds may be potentially used in the management of pain, opioid 
withdrawal symptoms and other illnesses (Boyer et al., 2008; Kumarnsit et al., 
2007a), it is pertinent to clarify in depth the abuse and addiction potential of these 
substances at its therapeutic doses as well as its mechanism of actions before any 
recommendation for its application in the patient treatments can be made. 
 
The rewarding properties of a particular substance may lead to drug dependence and 
addiction (Esch & Stefano, 2004; Koob & Le Moal, 2001). The rewarding properties 
can be assessed preclinically in animal model using CPP paradigm, a widely known 
screening tool for addictive potential of drug (Bardo & Bevins, 2000; Tzschentke, 
1998). A subject is said to develop CPP when it spent more time in a drug-paired 
environment, following several drug and vehicle pairings with neutral environment. 
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The drug-induced CPP occurs as a result of the acquisition (learning) and expression 
(retrieval of learning) phases (Carboni & Vacca, 2009). In the absence of drug, the 
established CPP can be maintained for a certain period of time, promoting drug-
seeking behaviour. In certain circumstances, this drug-induced CPP can be 
extinguished and reinstated, which could be of beneficial value to study drug relapse 
phenomenon in human (Mueller et al., 2002; Mueller & Stewart, 2000; Sakoori & 
Murphy, 2005).  
 
Different classes of drugs of abuse share a final common neuronal pathway for its 
rewarding effects, by activating the mesolimbic dopaminergic activity (Pierce & 
Kumaresan, 2006; Spanagel & Weiss, 1999; Wise, 1998). Their actions could be 
either by exerting direct influence on the dopamine (DA) neurones, and/or by 
altering other neurotransmitter systems that modulate the mesolimbic dopaminergic 
pathway (Pierce & Kumaresan, 2006; Tomkins & Sellers, 2001). Other than DA, the 
role of various neurotransmitter systems in the rewarding properties of drugs of 
abuse have been implicated, including opioidergic, ƴ-aminobutyric acid (GABA), 
serotonergic, cholinergic, glutamatergic, noradrenergic and endocannabinoid system 
(Mathon et al., 2003; Ross & Peselow, 2009). 
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1.2 Problem statements 
The available human reports on M. speciosa abuse and addiction (Ahmad & Aziz, 
2012; Saingam et al., 2013; Singh et al., 2014; Vicknasingam et al., 2010) have 
highlighted the need for comprehensive studies on the addictive properties of 
mitragynine in animal model of addiction. The elucidation of mitragynine’s 
rewarding properties in laboratory animals is required to reveal whether or not it 
contributes to M. speciosa dependence and abuse. Since mitragynine is the major 
constituent of the total alkaloid contents of M. speciosa plants cultivated in Malaysia 
(Chan et al., 2005), therefore, it may have a major role in the addictive effects 
exerted by this plant. Most of the drugs of abuse by human, such as morphine, posses 
rewarding properties, as indicated by the establishment of CPP in laboratory animals 
(Tzschentke, 1998), which is believed to be responsible for its abuse. Therefore, the 
present study was performed to examine the rewarding properties of mitragynine 
using CPP paradigm. It is hypothesized that mitragynine would exhibits CPP in the 
experimental animals based on the addictive features reported in human with regular 
M. speciosa consumption. 
 
In the absence of drug, the maintenance of the drug-induced CPP can promote drug-
seeking behaviour in laboratory animals (Mueller et al., 2002; Sakoori & Murphy, 
2005). Moreover, in human addicts, exposure to environment associated with drug 
increased the urge to use drug (Ludwig & Stark, 1974; O’Brien et al., 1977). 
Therefore, in the case of mitragynine, it is of interest to know whether the established 
mitragynine-induced CPP is maintained for extended periods of time and whether the 
environment associated with mitragynine is able to promote drug-seeking behaviour. 
It is hypothesized that mitragynine’s rewarding properties may persist over 
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considerable time and this would make the subjects attracted to the environment 
which has been previously associated with mitragynine. 
 
In laboratory animals, the drug-induced CPP could be extinguished when the subject 
is no longer exposed to the drug for a certain period of time (Mueller et al., 2002; 
Sakoori & Murphy, 2005) and this would lessen the desire to seek for the drug. 
Nevertheless, the drug-induced CPP could be triggered when the subject is 
reintroduced to the drug (Do Couto et al., 2003; Itzhak & Martin, 2002; Parker & 
McDonald, 2000). With regard to mitragynine, this has not yet been studied. 
Therefore, it is necessary to elucidate whether the mitragynine-induced CPP 
disappear following several extinction trainings, and whether the preference to 
mitragynine could be reinstated with priming mitragynine administration, after the 
extinction period. If mitragynine acts in a similar way as other drugs of abuse, it is 
hypothesized that mitragynine-induced CPP can be extinguished, and triggered by 
priming mitragynine administration following the extinction period. 
 
The brain reward mechanisms involve several interactions among multiple 
neurotransmitter systems (Ross & Peselow, 2009; Tomkins & Sellers, 2001). 
Previous observations revealed that the opioidergic, adrenergic, serotonergic and/or 
dopaminergic receptors play a role in several mitragynine’s activities (Matsumoto et 
al., 1996a,b; Thongpradichote et al., 1998), thus open a question for the role of these 
receptor systems in mitragynine reward, or CPP. Owing to the opioid characteristics 
showed by mitragynine (Matsumoto et al., 2005a; Taufik Hidayat et al., 2010; 
Watanabe et al., 1997), the current study tested the hypothesis that the opioid 
5 
 
receptor system would mediate the acquisition and expression of mitragynine-
induced CPP. 
 
The importance of GABAB receptor system on reward mechanism has been 
implicated in many studies (Le Foll et al., 2008; Li et al., 2001). For certain drugs of 
abuse, inhibition of GABAB activity partly mediates its rewarding effect, by 
releasing tonic inhibition exerted on DA neurones (Chen et al., 2005). Activation of 
opioid system has been demonstrated to inhibit the activity of GABAB on DA 
neurones (Spanagel & Weiss, 1999). Based on these facts, indirect involvement of 
GABAB receptor system in the acquisition and expression of mitragynine-induced 
CPP is sought to be an important issue that warrants further investigation. It is 
hypothesized that the GABAB receptor system involves in the pharmacological 
mechanisms underlying the opioid-mediated mitragynine-induced CPP. 
 
Drugs of abuse are well known to activate the mesolimbic dopaminergic activity as 
shown by the increased DA levels in the nucleus accumbens (NAc) (Di Chiara, 1998; 
Tomkins & Sellers, 2001). In addition, the increased NAc DA has been suggested to 
mediate the drug conditioned rewarding effects, or CPP (Shoaib et al., 1995). To 
date, there is no study performed to examine the activity of the dopaminergic system 
in brain reward areas following mitragynine administration. This posing a question 
whether acute mitragynine administration affects the release of extracellular DA 
levels within the brain areas that received dopaminergic projections. Therefore, 
investigation on the neurochemical events in the prefrontal cortex (PFC), NAc and 
caudate putamen (CPu) of the rat brain with regard to DA system following acute 
mitragynine administration was addressed in the present study. It is hypothesized that 
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mitragynine will increase the extracellular DA release, thus supports the effect of 
mitragynine on CPP paradigm.  
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1.3 Objectives 
In the present study, four specific objectives have been constructed to address the 
abovementioned problem statements: 
1. To investigate the locomotor effects of mitragynine as well as the 
establishment, maintenance, extinction and reinstatement of mitragynine-
induced CPP.  
2. To reveal the role of opioid receptor system on acquisition and expression of 
mitragynine-induced CPP using non-selective opioid receptor antagonist, 
naloxone. 
3. To elucidate the role of GABAB receptor system on acquisition and 
expression of mitragynine-induced CPP using GABAB receptor agonist, 
baclofen. 
4. To discover the effects of acute mitragynine administration on the 
extracellular release of DA and its metabolites, 3,4-dihydroxyphenylacetic 
acid and homovanillic acid, in the PFC, NAc and CPu regions using in vivo 
brain microdialysis coupled with high performance liquid chromatography-
electrochemical detector. 
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1.4 Summary of the research design 
 
 
 
 
 
  
 
  
 
 
Figure 1.1 Research design and the number of animals used in the study. 
Mitragynine-induced CPP 
and the profiles of DA and 
its metabolites in rats 
(n=422) 
Neurochemical study 
(n=40) 
 
Behavioural study 
(n=382) 
 
Locomotor and CPP effects of 
mitragynine (n=80) 
 
 Maintenance of mitragynine-induced 
CPP (n=24) 
 
 Extinction and reinstatement of 
mitragynine-induced CPP 
 
 
Role of opioid receptor system in the 
acquisition and expression of 
mitragynine-induced CPP (n=144) 
 
 Role of GABAB receptor system in the 
acquisition and expression of 
mitragynine-induced CPP (n=134) 
 
 
Extracellular changes of DA and its metabolites, DOPAC and 
HVA, in response to acute mitragynine exposure 
 
 
Characterization of 
mitragynine-induced 
CPP (n=104) 
 
Mechanisms 
underlying 
mitragynine-induced 
CPP (n=278) 
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1 Drug addiction 
Drug addiction can be classified as a chronic disease of the central nervous system 
(CNS), characterized by a loss of control over impulsive behaviour that leads to 
compulsive drug-seeking and drug-taking behaviour, and to relapse even after a long 
period of abstinence (Feltenstein & See, 2008). The clinical diagnosis of addiction 
includes the use of a psychoactive substance for a longer period or at higher doses 
than initially prescribed, drug cravings or failure to cease the drug use, compulsive 
drug taking despite negative consequences, increasing tolerance, withdrawal 
syndromes and desire to take the drug to mitigate these syndromes (Filip & 
Frankowska, 2008). 
 
2.1.1 Theories of addiction 
Early theories of addiction postulated that the ability of the substance to produce a 
pleasurable effect (reward) is the one that initiates drug consumption, and drug 
dependence occurs as a consequence of repeated drive for reward (Wise, 1980). The 
theory of positive reinforcement, which refers to the ability of the reinforcer (e.g.; 
addictive drug) to promote behavioural responses responsible for the pleasurable 
effects, has been accepted as a main factor that contributes to drug dependence. 
However, with repeated use, many drugs exhibit tolerance effect, a condition at 
which the reinforcing properties of the drug is attenuated, and therefore the drug 
dosage needs to be continually increased to maintain the desired effects. Meanwhile, 
some drugs produce sensitization on specific behaviours, as oppose to tolerance 
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effects. Based on these facts, the positive reinforcement theory alone is insufficiently 
strong to serve as the only causative factor for drug addiction. A negative 
reinforcement theory, which refers to continued drug use as a means to prevent the 
aversive consequences of drug withdrawal (aversive psychological and physiological 
effects), could account for the maintenance of compulsive drug use. Nevertheless, 
both positive and negative reinforcement theories are inadequate to comprehensively 
describe all aspects of addiction cycle, and several researchers have proposed some 
addiction theories which had a substantial influence on our understanding about 
addiction (Feltenstein & See, 2008). 
 
Koob & Le Moal (1997) have proposed that drug addiction is accompanied by the 
development of allostasis, a state where the brain reward regulatory system deviates 
chronically from its homeostatic level to new reward set points. The dysregulations 
of reward system with repeated drug intake result in an allostatic state that drives 
further drug intake, and ultimately lead to compulsive drug use, and in turn 
exaggerates the allostatic state. The process of maintaining the reward function 
stability is hypothesized to involve alterations in reward neurotransmission 
(mesolimbic dopamine and opioid peptide system) as well as brain (corticotrophin-
releasing factor; CRF, neuropeptide Y; NPY and norepinephrine system) and 
hormonal stress system (hypothalamic-pituitary-adrenal; HPA axis). 
 
Alternatively, Robinson & Kent (1993) have suggested an incentive sensitization 
theory of addiction, whereby recurrent use of addictive drugs can persistently alter 
the neural circuits that normally involves in motivated behaviour, including incentive 
motivation and reward for natural appetitive reinforcers. These neuroadaptations 
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cause the brain circuits hypersensitive to the drug and drug-associated stimuli, thus 
results in a transition from drug ‘liking’ to drug ‘wanting’ behaviour. This 
pathological incentive motivation for drugs last for years resulted from the persistent 
incentive sensitization.  
 
Several research groups had made an assumption that a shift to addiction stems from 
aberrant learning caused by the drug itself. The implicit stimulus-response learning 
promotes the progression from initially conscious behaviour to more automatically 
(unconscious) habit behaviour (Everitt & Robbins, 2005; Robinson & Berridge, 
2003; Wise, 2002). In another point of view, Jentsch & Taylor (1999) have 
postulated that alterations in the cortical and limbic circuits causing deficits in 
behavioural control, impaired decision-making processes as well as augmented 
incentive motivational qualities of the drug and drug-associated stimuli.  
 
2.1.2 Neurobiology of addiction 
Activation of dopaminergic mesocorticolimbic system that arises from the ventral 
tegmental area (VTA) of the midbrain accounts for the final common neuronal 
pathway by which various drugs of abuse mediate their acute reinforcing effects 
(Pierce & Kumaresan, 2006; Spanagel & Weiss, 1999; Wise, 1998). This 
dopaminergic mesocorticolimbic system plays pivotal roles in reward, motivational 
control and modulation of cognitive functions. The mesolimbic circuit includes 
projections from cell bodies of the VTA to limbic structures such as nucleus 
accumbens (NAc), amygdala and hippocampus (Figure 2.1). Meanwhile, the 
mesocortical circuit includes projections from the VTA to the PFC, orbitofrontal 
cortex, and anterior cingulate. The activation of VTA DA neurones lead to an 
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increase in dopaminergic neuronal firing rate as well as DA synthesis and release. 
The increased DA concentration in the NAc appears to be responsible for the 
rewarding effects or feeling pleasure (Koob & Le Moal, 1997).  
 
 
Figure 2.1 Brain reward circuit (adapted from Kalsi et al., 2009). 
 
 
Other than the addictive drugs, natural rewards such as food, drink and sex also 
stimulate the release of DA into the NAc, producing euphoric effect. As for the 
natural rewards, novelty contributes to the initial response, and habituation occurs 
after a few experiences. In the case of addictive drugs, the concentration of NAc DA 
increases as the drug dosage increases. Overstimulation of DA will then results in 
dysregulation of the natural reward pathways as well as learning process in the brain 
(Cami & Farre, 2003; Di Chiara, 1998).  
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DA is a catecholamine, a subclass of the monoamine neurotransmitters synthesized 
from an amino acid known as tyrosine (Yang & Beal, 2011). The synthesis of DA 
and its metabolism are depicted in Figure 2.2. In the dopaminergic neurones, tyrosine 
is converted to 3,4-dihydroxyphenylalanine (L-DOPA) by the cytosolic enzyme 
tyrosine hydroxylase (TH). Aromatic amino acid decarboxylase (AADC) converts 
cytosolic L-DOPA to DA. From the cytoplasm, DA is stored in specialized storage 
vesicles until the arrival of an action potential, whereby DA is being released into the 
synapse by a process of exocytosis. In normal conditions, the reuptake mechanisms 
by presynaptic DA transporter (DAT) are responsible for transporting extracellular 
DA back into the cytoplasmic nerve terminal. In the cytoplasm, DA is either 
repacked into storage vesicles or broken down by the enzyme monoamine oxidase 
(MAO) to DOPAC. The extracellular DA left in the synaptic gap is methylated to 3-
methoxytyramine (3-MT) by the enzyme catecholamine-O-methyltransferase 
(COMT), which can be taken back into the cytoplasm and further oxidized to HVA 
by MAO. The cytoplasmic DOPAC may leak out to the extracellular space and be 
methylated to HVA by COMT. The determination of DA and its metabolites 
DOPAC and HVA in biological samples provides an important key to understand the 
neurobiology of addiction (Yang & Beal, 2011). The molecular structure of DA, 
DOPAC and HVA are shown in Figure 2.3. 
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Figure 2.2 Schematic representation of dopamine synthesis and metabolism (AADC: 
aromatic amino acid decarboxylase; COMT: catechol-O-methyltransferase; DOPAC: 
3,4-dihydroxyphenylacetic acid; HVA: homovanillic acid; L-DOPA: 3,4-
dihydroxyphenylalanine; MAO: monoamine oxidase; 3-MT: 3-methoxytyramine; 
TH: tyrosine hydroxylase) (adapted from Mazzio et al., 2011). 
 
 
 
 
 
Figure 2.3 Structure of DA and its metabolites (adapted from Cai et al., 2010). 
 
 
The physiological actions of DA are mediated by five distinct G protein-coupled 
receptor subtypes (Bressan & Crippa, 2005). Two D1-like receptor subtypes (D1 and 
D5) coupled to G protein causes activation of adenylyl cyclase and stimulate cyclic 
adenosine 3’,5’-monophosphate (cAMP) formation whereas the D2-like receptor 
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subtypes (D2, D3 and D4) coupled to G protein causes inhibition of adenylyl cyclase 
and activate potassium (K
+
) channels. The expression of both D1 and D2 receptors 
differs in distinct neuronal populations that project to different brain regions (Bressan 
& Crippa, 2005).  
 
Despite dopaminergic system, converging evidence have implicated the role of 
various neurotransmitter systems in acute reinforcing properties of drugs of abuse, 
including opioidergic, ƴ-aminobutyric acid (GABA), serotonergic, cholinergic, 
glutamatergic, noradrenergic and endocannabinoid system (Mathon et al., 2003). 
Each of these systems acts either in parallel with dopaminergic system or via 
independent pathways of reinforcement (Ross & Peselow, 2009). Among these, the 
involvement of opioid and GABA systems in mediating the reward processes are 
chosen as subject of interest in the present study. 
 
GABA is the main inhibitory neurotransmitters in the mammalian CNS (Chalifoux & 
Carter, 2011). Immunocytochemical studies revealed that GABA is the most 
abundant non-dopaminergic cells in the VTA. These GABAergic neurones project to 
the NAc, as well as other brain regions (Steffensen et al., 1998; Van Bockstaele & 
Pickel, 1995). Several lines of evidence suggested that GABAergic interneurones 
provide tonic inhibitory control over dopaminergic neuronal activity in the VTA 
(Chen et al., 2005; Xi & Stein, 2002). GABA causes hyperpolarisation either by 
acting on ionotropic GABAA/C or metabotropic GABAB receptors. GABAA receptors 
are ligand-gated chloride (Cl
-
) channel that mediate the fast synaptic inhibition, while 
GABAB receptors are linked to K
+
 channel through G protein and mediate slow onset 
of actions (Mathon et al., 2003; Zarrindast et al., 2006) . The GABAergic system is 
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crucial in modulating the rewarding effects of addictive drugs, particularly through 
GABAB receptors (Spano et al., 2007) since majority of GABAA receptors in the 
VTA are not located on DA neurones (Churchill et al., 1992). The GABAB receptor 
exists as a heterodimer which composed of GABAB(1) and GABAB(2) subunits. The 
agonist binding site resides on the GABAB(1) subunit whereas the GABAB(2) subunit 
links to G proteins (Chen et al., 2005). Previous studies have indicated that 
stimulation of GABAB receptors reduced the dopaminergic cell firing and bursting 
activity in the VTA (Erhardt et al., 2002). Moreover, GABAB receptor agonists are 
effective in the treatment of substance abuse disorders (Filip & Frankowska, 2008). 
Baclofen, a lipophilic GABAB receptor agonist, has been reported to cause reduction 
in the reinforcing effects of several addictive drugs, such as opiates, cocaine and 
nicotine (Fadda et al., 2003). In addition, GABAB receptor activation results in 
attenuation of methamphetamine, cocaine, heroin, alcohol and nicotine self-
administration in rodents (Brebner et al., 2002). Enhancement of GABAergic 
transmission also inhibit conditioned place preference effects induced by morphine 
(Kaplan et al., 2003; Zarrindast et al., 2006), methamphetamine (Li et al., 2001) and 
nicotine (Le Foll et al., 2008) in rats. 
 
Besides GABA, extensive studies have shown the modulatory role of opioidergic 
system in motivational processes and rewarding behaviours (Narita et al., 2001; Self 
& Stein, 1992; Van Ree et al., 1999). The opioid receptors are mainly classified into 
mu (µ), delta (δ) and kappa (к) subtypes (Kieffer & Evans, 2009). The µ-opioid 
receptors primarily mediate the rewarding effects of both opioid and non-opioid 
drugs, although δ-opioid receptor system has also been implicated in the rewarding 
processes. In contrast, stimulation of к-opioid receptor produces aversive events 
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(Liang et al., 2006). Activation of µ-opioid receptors enhance DA neurotransmission 
by inhibiting GABAergic interneurones, thereby disinhibiting mesolimbic DA 
neurones and increasing both somatodendritic and axonal DA release (Spanagel & 
Weiss, 1999). Administration of µ-opioid agonists such as morphine and endogenous 
opioid peptide, endomorphin-1 produced conditioned place preference effect, a 
behavioural measure of drug-induced reward, as a result of increased DA release in 
the mesolimbic regions (Terashvili et al., 2008). In addition, selective agonists acting 
at µ-opioid receptors supported self-administration behaviour induced by morphine. 
Conversely, application of opioid antagonists such as naloxone effectively blocked 
both morphine-induced conditioned place preference and morphine self-
administration, therefore strengthening the roles of opioid receptors in mediating the 
reward mechanisms (Van Ree et al., 1999). 
 
2.1.3 Molecular and cellular adaptations in addiction 
Repeated exposure to the addictive drugs may gradually and progressively develop 
several addictive behaviours that can sustain after a long period of abstinence. 
Alterations of gene expression in specific brain regions have been suggested to 
mediate the persistence of the addictive behaviours in drug addicts through changes 
in transcription factors.Administration of drug of abuse causes changes in various 
intracellular signalling pathways, eventually signals to the cell nucleus leading to 
alteration of transcription factors. These transcription factors bind to the regulatory 
region of the DNA hence controlling the rate of gene transcription. To date, drugs of 
abuse have been demonstrated to cause alterations in numerous types of transcription 
factors, including cAMP response element binding protein (CREB) (Nestler, 2004). 
CREB is one of the transcription factors that mediate the effects of cAMP second 
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messenger pathway on gene expression. Up-regulation of the cAMP pathway is the 
best established molecular adaptation to chronic drug exposure. This occurs through 
the phosphorylation of CREB on a single serine residue, namely Ser133, by protein 
kinase A, which is activated by cAMP. After phosphorylation process, CREB dimers 
bind to specific cAMP response element (CRE) sites and regulate the transcription of 
target genes via interaction with basal transcriptional complex. Several lines of 
evidence have implicated drug-induced activation of CREB underlying up-regulation 
of cAMP pathway in NAc, VTA, amygdala, hippocampus, lateral hypothalamus, 
frontal cortex and locus ceruleus (Nestler, 2004). 
 
2.1.4 Drugs of abuse 
The drugs of abuse can generally be classified into different categories, including 
psychostimulants (cocaine, amphetamine), cannabinoids (marijuana), depressants 
(ethanol), hallucinogens (ecstacy), inhalants (toluene) and opiates (morphine, heroin) 
(Feltenstein & See, 2008). Virtually all abused drugs have a common ability to 
produce rewarding effects and/or relieve negative emotional states by enhancement 
of dopaminergic activity (Feltenstein & See, 2008). These drugs exert their actions 
either by directly influencing the principal DA neurones (either by opening or 
closing specific ion channels or through second messenger systems) or by acting 
specifically on secondary neurones that modulates the dopaminergic neurones 
(Mathon et al., 2003). 
 
Psychostimulants exert its euphoric effects through interactions with DA 
transporters. While cocaine blocks the activity of DA transporters which reduce the 
rate of DA reuptake, most amphetamine derivatives increased DA concentration by 
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reversing the action of transporters at the plasma membrane (Luscher & Ungless, 
2006; Pierce & Kumaresan, 2006). 
 
Nicotine is the main psychoactive compound founds in tobacco (Tomkins & Sellers, 
2001). Increased DA release in the NAc following nicotine administration mainly 
results from direct stimulation of nicotinic acetylcholine receptors. Nicotine binds to 
the nicotinic acetylcholine receptors in the brain, become cation-permeable and 
depolarise the cell leading to an increase in DA concentration (Luscher & Ungless, 
2006). These ionotropic receptors are expressed on GABA and dopaminergic 
neurones, as well as glutamatergic inputs to DA neurones (Pierce & Kumaresan, 
2006). 
 
∆9-tetrahydrocannabinol (THC), the active ingredient in cannabis, mainly binds to 
the type 1 cannabinoid receptors (CB1Rs) (Feltenstein & See, 2008; Luscher & 
Ungless, 2006). These receptors are highly expressed in several brain regions 
including the VTA, NAc, cortex, hippocampus and striatum. In the VTA, these 
receptors are expressed on the GABA neurones and on terminals of glutamatergic 
synapses on DA neurones (Feltenstein & See, 2008; Luscher & Ungless, 2006). It 
has been demonstrated that application of THC in acute midbrain slices causes a net 
disinhibition by decreasing GABA release (Szabo et al., 2002). 
 
Since ethanol has complex pharmacological effects within the brain, a wide variety 
of neurotransmitter systems have been linked to its reinforcing effects, such as 
GABA (GABAA receptors), opioid peptides (δ receptors), glutamate (NMDA 
receptors), acetylcholine (nicotinic receptors) and serotonin (5-HT3 receptors) 
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(Feltenstein & See, 2008; Koob & Le Moal, 1997; Luscher & Ungless, 2006). 
Ethanol increased the NAc DA release either by direct or indirect modulation of the 
mesolimbic DA activity (Tomkins & Sellers, 2001). 
 
Morphine exerts its rewarding action primarily by binding to µ-opioid receptors. The 
direct action of morphine is inhibitory, therefore, the excitatory effects of morphine 
on VTA dopaminergic neurotransmission occurs via indirect mechanisms (Tsuji et 
al., 1996). Previous report has indicated that the VTA DA neurones are under tonic 
inhibition of GABAergic interneurones (Johnson & North, 1992). Anatomical 
evidence has suggested that µ-opioid receptors are predominantly expressed on 
GABAergic interneurones of the VTA (Mansour et al., 1988). µ-opioid receptors 
have dual action, either acting post-synaptically or pre-synaptically (Luscher & 
Ungless, 2006). µ-opioid receptors expressed on the post-synaptic terminals 
hyperpolarise GABA neurones mediated by Kir3/G protein-coupled inwardly 
rectifying K
+
 (GIRK) channels coupled to µ-opioid receptors on the soma and the 
dendrites, which in turn reduces GABA release. Meanwhile, µ-opioid receptors 
expressed on the presynaptic terminals decreased GABA release by inhibiting 
calcium (Ca
2+
) channels or activating voltage-gated K
+
 channels. These dual actions 
of µ-opioid receptors lead to a strong inhibition of GABA neurones which 
contributes to the disinhibition of DA neurones, resulting in augmented DA release 
in the NAc (Luscher & Ungless, 2006). 
 
2.1.5 Drug dependence and relapse (reinstatement) 
Contradictory to the significant increase in neurotransmitter activity (DA) following 
acute drug exposure, chronic administration of addictive drugs involves complex 
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alterations in the NAc activity (Feltenstein & See, 2008). The persistent alterations in 
stress hormone system, receptor and/or neurotransmitter activity act as compensatory 
mechanisms for restoring homeostatic functions in response to the drug. These 
changes could account for the negative emotional states manifested after drug 
withdrawal, as well as enhanced sensitivity to stressful stimuli, which both could 
lead to greater vulnerability to relapse (Koob & Le Moal, 1997; Weiss, 2005). 
 
Relapse to drug use after prolonged periods of abstinence is a core feature of drug 
addiction and becomes the foremost challenge to the drug addiction treatment 
(Mueller & Stewart, 2000). With the use of reinstatement model in laboratory 
animals, relapse can be measured when the response to the drug is reinitiated, 
following the establishment and subsequent extinction of particular behaviour 
response. Reinstatement can be defined as recovery of a learned response when a 
subject is exposed to an unconditioned stimulus after extinction. The major 
precipitating factors for reinstatement include interactions with stimuli previously 
associated with the drug, exposure to the drug itself, and/or stressors (Aguilar et al., 
2009). To date, the development and application of reinstatement model of relapse 
have contributed towards neurocircuitry mapping essential for maintaining the 
relapse-like behavior. From previous findings, it appears that the neurocircuits 
involved in cue-, drug- and stress-induced reinstatement of drug-seeking behavior are 
distinct, yet overlapping. Evidence has shown the interactions of dorsomedial 
prefrontal cortex (dmPFC), amygdala and VTA with the NAc core via glutamatergic 
and dopaminergic pathways in the reinstatement of cue-induced drug-seeking 
behavior. In another studies, dmPFC glutamatergic projections to the NAc core and 
dopaminergic innervations of the dmPFC and NAc shell play important roles in 
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mediating relapse behavior following exposure to the previously administered drug. 
Increased drug craving and relapse following exposure to stressful stimuli, such as 
acute foot shock and administration of noradrenergic α2 receptor antagonist, 
yohimbine, a drug that exert anxiety-like states in both humans and animals, are 
suggested to be attributed by CRF and noradrenergic inputs to the central nucleus of 
amygdala and the lateral bed nucleus of the stria terminalis that serially project to the 
dmPFC and NAc core. In addition, other brain structures such as dorsal striatum, 
dorsal hippocampus and NAc shell, may play critical roles in producing drug-seeking 
behavior, depending upon the nature of the withdrawal history or contextual 
environment that triggers relapse (Feltenstein & See, 2008). 
 
Functional brain imaging in humans as well as brain lesion and site-specific 
pharmacological manipulations in animals have acknowledged an interconnected set 
of cortical and limbic brain regions in associative learning mediating craving and 
relapse. Among components of this circuitry include the orbitofrontal cortex, anterior 
cingulate, prelimbic cortex, basolateral amygdala, hippocampus, NAc, and dorsal 
striatum (Weiss, 2005). 
 
2.1.6 Animal models of addiction 
The use of animal models has provided an invaluable means for understanding the 
neurobiology of addiction and mechanisms of action of abused drugs. Examples of 
such models include intracranial electrical self-stimulation, drug self-administration 
paradigms and conditioned place preference. 
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(a) Intracranial electrical self-stimulation 
Intracranial electrical self-stimulation (ICSS) is useful for localizing brain regions 
that mediate drug reward, as well as elucidating the brain reward mechanisms. In the 
ICSS procedure, animal is equipped with electrodes implanted into specific brain 
regions. Specific behavioural response (e.g.; pressing a lever) will be followed by a 
short-pulse train of electrical current via the electrode. Animal will initiate and 
maintain lever-pressing for obtaining the stimulus if the electrodes were implanted in 
brain areas associated with reward pathways (Van Ree et al., 1999). 
 
(b) Drug self-administration 
Drug self-administration model has been extensively used in basic and preclinical 
drug abuse research. It is based on the concept of operant conditioning, in which 
animals are trained to perform an operant behaviour (e.g.; nose poke or lever press) 
for a certain stimulus (e.g.; administration of a drug). The drug is said to be self-
administered, and serves as a positive reinforcer, when the frequency of the 
behavioural response is increased. In a controlled laboratory setting, animals self-
administer drugs that consumed by human for recreational purposes, including 
opiates, cannabinoids, alcohol, nicotine, amphetamine and cocaine. Most of the 
intravenous self-administration studies employ rats and monkeys to assess the 
reinforcing effects of drugs. However, other species such as dogs, cats, mice and 
pigeons, have been used. For this method, several routes of drug administration were 
developed, including intragastric, oral, inhalation, intracerebroventricular, and 
intracerebral (Van Ree et al., 1999).  
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(c) Conditioned place preference (CPP) 
CPP paradigm, which is a standard preclinical behavioural test, has been widely used 
to assess the motivational, including rewarding and aversive effects of drugs 
(Tzschentke, 1998). Generally, addiction can be characterized by a loss of 
behavioural control over the desired drug due to its unconditioned or rewarding 
properties. In the absence of drug, the drug-associated stimuli can acquire the 
abilities to control the behaviours. CPP takes place when a subject prefers an 
environment (conditioned stimulus) over the other because the preferred environment 
has been previously associated with pleasurable or rewarding events (unconditioned 
stimulus). The drug-associated conditioned stimuli are presumed to be responsible 
for drug craving and relapse. Most drugs of abuse, such as morphine, amphetamine, 
cocaine, ethanol and nicotine, elicit a CPP in laboratory animals (Tzschentke, 1998). 
CPP has been demonstrated in various species, including zebrafish, flies, mice, rats, 
primates and humans (Huston et al, 2013; Mathur et al., 2011). Despite addictive 
drugs, natural stimuli such as food and sexual activity also produce CPP. In addition, 
conditioned place aversion (CPA) of a particular drug stimulus can be detected using 
place conditioning paradigm. CPA refers to the avoidance behaviour of a subject for 
one place over the other because of the previously associated aversive events 
(Tzschentke, 1998). 
 
There are numerous methodological approaches reported in performing the CPP 
based on the route of drug administration (e.g.; intraperitoneal, subcutaneous), the 
choice (e.g.; mice, rat) and age (e.g.; adolescent, adult) of the model organism, as 
well as design of the conditioning chamber (e.g.; two chambers, three chambers) and 
experiments (e.g.; biased, unbiased) (Bardo et al., 1995).  
